E-ISSN 2305-1620 | ISSN 2221-0288
 

Original Research (Original Article) 


Lactate dehydrogenase (LDH) as predictive factor of the pain free syndrome duration after radionuclide treatment of bone metastases in patients with breast cancer

Nigora Rasulova, Dauranbek Arybzhanov, Vladimir Lyubshin, Abdulla Abdikhakimov, Shamsutdin Sagdullaev,Sherzod Nishonov, Gayrat Arifhodjaev,Yuliya Shakirova, Valery Krylov, Marat Khodjibekov.

Abstract
Aims: The purpose of this study was to investigate a possible role of serum LDH as a predictor of cancer cell activity and to determine if serum LDH levels can prognosticate the duration of pain-free period after radionuclide therapy. <br> Methods: The We selected 62 breast cancer patients with ages ranging from 29-67 years (mean age 53.2 ± 9.5 years) who had a successful response to radionuclide therapy with 153Sm-oxabifore and had their serum LDH levels determined prior to the therapy. Patients with a history of a benign disease, which could possibly influence the serum LDH levels, or those suffering from complications such as a vertebral fracture or impending cord compression, were excluded from the study. <sup>153</sup>Sm-oxabifore was administrated in a standard dose of 37 MBq per kg body weight. All patients were on bisphosphonate therapy, both before and after samarium-153 treatment. Group 1 comprised of 23 patients who had received combined <sup>153</sup>Sm-oxabifore and zoledronic acid therapy. Group 2 comprised of 39 patients who had additionally received therapy for their primary tumour. For each of these two groups, the correlation between serum LDH levels and duration of the pain-free syndrome was estimated. <br> Results: There was a strong negative correlation (r = -0.84) between the serum LDH levels and the duration of pain-free period in Group 1, but no significant correlation (r = 0.1) was seen between the LDH levels and the duration of pain-free period in Group 2. The duration of pain-free period in the second group was longer in comparison to the first group and was statistically significant (p < 0.0001). <br> Conclusion: Serum LDH level can prognosticate the duration of the pain-free period after radionuclide therapy and could be useful in selecting patients who in addition to samarium-153 therapy may additionally benefit from treatment of the primary tumour.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
Print this article Print this Article
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Nigora Rasulova
Articles by Dauranbek Arybzhanov
Articles by Vladimir Lyubshin
Articles by Abdulla Abdikhakimov
Articles by Shamsutdin Sagdullaev
Articles by Sherzod Nishonov
Articles by Gayrat Arifhodjaev
Articles by Yuliya Shakirova
Articles by Valery Krylov
Articles by Marat Khodjibekov
on Google
on Google Scholar
Article Statistics
 Viewed: 3763
Downloaded: 241
Cited: 0

How to Cite this Article
Pubmed Style

Nigora Rasulova, Dauranbek Arybzhanov, Vladimir Lyubshin, Abdulla Abdikhakimov, Shamsutdin Sagdullaev,Sherzod Nishonov, Gayrat Arifhodjaev,Yuliya Shakirova, Valery Krylov, Marat Khodjibekov. Lactate dehydrogenase (LDH) as predictive factor of the pain free syndrome duration after radionuclide treatment of bone metastases in patients with breast cancer. Pak J Nucl Med. 2016; 6(1): 11-18.


Web Style

Nigora Rasulova, Dauranbek Arybzhanov, Vladimir Lyubshin, Abdulla Abdikhakimov, Shamsutdin Sagdullaev,Sherzod Nishonov, Gayrat Arifhodjaev,Yuliya Shakirova, Valery Krylov, Marat Khodjibekov. Lactate dehydrogenase (LDH) as predictive factor of the pain free syndrome duration after radionuclide treatment of bone metastases in patients with breast cancer. http://www.pjnmed.com/?mno=284644 [Access: December 15, 2019].


AMA (American Medical Association) Style

Nigora Rasulova, Dauranbek Arybzhanov, Vladimir Lyubshin, Abdulla Abdikhakimov, Shamsutdin Sagdullaev,Sherzod Nishonov, Gayrat Arifhodjaev,Yuliya Shakirova, Valery Krylov, Marat Khodjibekov. Lactate dehydrogenase (LDH) as predictive factor of the pain free syndrome duration after radionuclide treatment of bone metastases in patients with breast cancer. Pak J Nucl Med. 2016; 6(1): 11-18.



Vancouver/ICMJE Style

Nigora Rasulova, Dauranbek Arybzhanov, Vladimir Lyubshin, Abdulla Abdikhakimov, Shamsutdin Sagdullaev,Sherzod Nishonov, Gayrat Arifhodjaev,Yuliya Shakirova, Valery Krylov, Marat Khodjibekov. Lactate dehydrogenase (LDH) as predictive factor of the pain free syndrome duration after radionuclide treatment of bone metastases in patients with breast cancer. Pak J Nucl Med. (2016), [cited December 15, 2019]; 6(1): 11-18.



Harvard Style

Nigora Rasulova, Dauranbek Arybzhanov, Vladimir Lyubshin, Abdulla Abdikhakimov, Shamsutdin Sagdullaev,Sherzod Nishonov, Gayrat Arifhodjaev,Yuliya Shakirova, Valery Krylov, Marat Khodjibekov (2016) Lactate dehydrogenase (LDH) as predictive factor of the pain free syndrome duration after radionuclide treatment of bone metastases in patients with breast cancer. Pak J Nucl Med, 6 (1), 11-18.



Turabian Style

Nigora Rasulova, Dauranbek Arybzhanov, Vladimir Lyubshin, Abdulla Abdikhakimov, Shamsutdin Sagdullaev,Sherzod Nishonov, Gayrat Arifhodjaev,Yuliya Shakirova, Valery Krylov, Marat Khodjibekov. 2016. Lactate dehydrogenase (LDH) as predictive factor of the pain free syndrome duration after radionuclide treatment of bone metastases in patients with breast cancer. Pakistan Journal of Nuclear Medicine, 6 (1), 11-18.



Chicago Style

Nigora Rasulova, Dauranbek Arybzhanov, Vladimir Lyubshin, Abdulla Abdikhakimov, Shamsutdin Sagdullaev,Sherzod Nishonov, Gayrat Arifhodjaev,Yuliya Shakirova, Valery Krylov, Marat Khodjibekov. "Lactate dehydrogenase (LDH) as predictive factor of the pain free syndrome duration after radionuclide treatment of bone metastases in patients with breast cancer." Pakistan Journal of Nuclear Medicine 6 (2016), 11-18.



MLA (The Modern Language Association) Style

Nigora Rasulova, Dauranbek Arybzhanov, Vladimir Lyubshin, Abdulla Abdikhakimov, Shamsutdin Sagdullaev,Sherzod Nishonov, Gayrat Arifhodjaev,Yuliya Shakirova, Valery Krylov, Marat Khodjibekov. "Lactate dehydrogenase (LDH) as predictive factor of the pain free syndrome duration after radionuclide treatment of bone metastases in patients with breast cancer." Pakistan Journal of Nuclear Medicine 6.1 (2016), 11-18. Print.



APA (American Psychological Association) Style

Nigora Rasulova, Dauranbek Arybzhanov, Vladimir Lyubshin, Abdulla Abdikhakimov, Shamsutdin Sagdullaev,Sherzod Nishonov, Gayrat Arifhodjaev,Yuliya Shakirova, Valery Krylov, Marat Khodjibekov (2016) Lactate dehydrogenase (LDH) as predictive factor of the pain free syndrome duration after radionuclide treatment of bone metastases in patients with breast cancer. Pakistan Journal of Nuclear Medicine, 6 (1), 11-18.





Most Viewed Articles
  • Behaviour of wedges for different field sizes and depths
    Sajjad Ahmed Memon, Naeem Ahmed Laghari, Fayaz Hussain Mangi
    Pak J Nucl Med. 2017; 7(1): 20-27
    » Abstract » doi: 10.24911/PJNMed.7.4

  • Determination of the optimum filter for 99mTc SPECT breast imaging using a wire mesh collimator
    Xianling Dong, M.I. Saripan, R. Mahmud, S. Mashohor, Aihui Wang
    Pak J Nucl Med. 2017; 7(1): 9-15
    » Abstract » doi: 10.24911/PJNMed.7.2

  • Clinical characteristics and long-term outcome of patients with differentiated carcinoma of thyroid with bone metastases: a retrospective study
    Sadaf Tufail Butt, Shazia Fatima, Noreen Marwat, Kahkashan Mir, Ayesha Ammar, Mohammad Faheem
    Pak J Nucl Med. 2017; 7(1): 34-37
    » Abstract » doi: 10.24911/PJNMed.7.6

  • Pre-operative cardiac risk stratification for noncardiac surgery in cancer patients using myocardial perfusion scintigraphy
    Iqbal Munir, Amrah Javaid, Khalid Nawaz, Mohammed Hathaf Al-Rowaily, Muaadh Abdualrehman Al-Asbahi
    Pak J Nucl Med. 2017; 7(1): 28-33
    » Abstract » doi: 10.24911/PJNMed.7.5

  • A brief review of targetted radionuclide therapies
    Mohammed Hathaf Al-Rowaily, Daniele Dondi, MarcoChinol, Iqbal Munir, Muaadh Abdualrehman Alasbahi
    Pak J Nucl Med. 2017; 7(1): 4-8
    » Abstract » doi: 10.24911/PJNMed.7.1

  • Bone scintigraphy in apatite-associated destructive arthritis (Milwaukee shoulder syndrome)
    Qaisar Hussain Siraj
    Pak J Nucl Med. 2017; 7(1): 44-47
    » Abstract » doi: 10.24911/PJNMed.7.9

  • Successful Ra-223 treatment with a long interval between the second and the third cycles: a case report
    Tatiana Kochetova, Valeriy Krylov
    Pak J Nucl Med. 2017; 7(1): 38-41
    » Abstract » doi: 10.24911/PJNMed.7.7

  • Measurement of radiation doses to occupational workers in nuclear medicine
    Misbah Javed, Saeed Ur Rahman, Iqra Tanveer, Ghulam Asghar, Shazia Fatima, Mohammad Fahim
    Pak J Nucl Med. 2017; 7(1): 16-19
    » Abstract » doi: 10.24911/PJNMed.7.3

  • Cutaneous flow pattern of primary lymphoedema
    Qaisar Hussain Siraj
    Pak J Nucl Med. 2017; 7(1): 42-43
    » Abstract » doi: 10.24911/PJNMed.7.8

  • Unusual breast radioiodine uptake in a nonbreastfeeding woman with papillary thyroid carcinoma
    Yassir Benameur, Hasnae Guerrouj, Salah Nabih Oueriagli,Omar Ait Sahel, Imad Ghfir, Nouzha Ben Ras Aouad
    Pak J Nucl Med. 2017; 7(1): 51-52
    » Abstract » doi: 10.24911/PJNMed.7.11

  • Most Downloaded
  • Clinical characteristics and long-term outcome of patients with differentiated carcinoma of thyroid with bone metastases: a retrospective study
    Sadaf Tufail Butt, Shazia Fatima, Noreen Marwat, Kahkashan Mir, Ayesha Ammar, Mohammad Faheem
    Pak J Nucl Med. 2017; 7(1): 34-37
    » Abstract » doi: 10.24911/PJNMed.7.6

  • Determination of the optimum filter for 99mTc SPECT breast imaging using a wire mesh collimator
    Xianling Dong, M.I. Saripan, R. Mahmud, S. Mashohor, Aihui Wang
    Pak J Nucl Med. 2017; 7(1): 9-15
    » Abstract » doi: 10.24911/PJNMed.7.2

  • Successful Ra-223 treatment with a long interval between the second and the third cycles: a case report
    Tatiana Kochetova, Valeriy Krylov
    Pak J Nucl Med. 2017; 7(1): 38-41
    » Abstract » doi: 10.24911/PJNMed.7.7

  • A brief review of targetted radionuclide therapies
    Mohammed Hathaf Al-Rowaily, Daniele Dondi, MarcoChinol, Iqbal Munir, Muaadh Abdualrehman Alasbahi
    Pak J Nucl Med. 2017; 7(1): 4-8
    » Abstract » doi: 10.24911/PJNMed.7.1

  • Behaviour of wedges for different field sizes and depths
    Sajjad Ahmed Memon, Naeem Ahmed Laghari, Fayaz Hussain Mangi
    Pak J Nucl Med. 2017; 7(1): 20-27
    » Abstract » doi: 10.24911/PJNMed.7.4

  • Measurement of radiation doses to occupational workers in nuclear medicine
    Misbah Javed, Saeed Ur Rahman, Iqra Tanveer, Ghulam Asghar, Shazia Fatima, Mohammad Fahim
    Pak J Nucl Med. 2017; 7(1): 16-19
    » Abstract » doi: 10.24911/PJNMed.7.3

  • Cutaneous flow pattern of primary lymphoedema
    Qaisar Hussain Siraj
    Pak J Nucl Med. 2017; 7(1): 42-43
    » Abstract » doi: 10.24911/PJNMed.7.8

  • Pre-operative cardiac risk stratification for noncardiac surgery in cancer patients using myocardial perfusion scintigraphy
    Iqbal Munir, Amrah Javaid, Khalid Nawaz, Mohammed Hathaf Al-Rowaily, Muaadh Abdualrehman Al-Asbahi
    Pak J Nucl Med. 2017; 7(1): 28-33
    » Abstract » doi: 10.24911/PJNMed.7.5

  • A striking case of florid multifacial soft-tissue infection on an FDG-PET scan
    Qaisar Hussain Siraj, Amir Javaid, Nigora Rasulova
    Pak J Nucl Med. 2017; 7(1): 48-50
    » Abstract » doi: 10.24911/PJNMed.7.10

  • Unusual breast radioiodine uptake in a nonbreastfeeding woman with papillary thyroid carcinoma
    Yassir Benameur, Hasnae Guerrouj, Salah Nabih Oueriagli,Omar Ait Sahel, Imad Ghfir, Nouzha Ben Ras Aouad
    Pak J Nucl Med. 2017; 7(1): 51-52
    » Abstract » doi: 10.24911/PJNMed.7.11

  • Most Cited Articles